Haloperidol (Haldol)

Drug Profile

Brand Haldol Potency High
Class First Generation Antipsychotic Sedation Yes
Receptor D2 (nigrostriatal pathway)
Routes PO/IM

Oral (PO) Dosing

Starting Titration Therapeutic
2mg PO
2mg PO q2weeks
15mg PO (max 25mg)
2-5mg q1h PO/IM (Max 20mg/24hr) Slowly over 6-8 weeks PO = 12-38hrs, IM = 3 weeks
  • Psychotic Disorders (oral, immediate release injection)
  • Tics and vocal utterances in Tourette’s Disorder (oral, immediate release injection)
  • Second-line treatment of severe behavior problems in children of combative, explosive hyperexcitability (oral, immediate release injection)
  • Second-line short-term treatment of hyperactive children (oral, immediate release injection)
  • Treatment of schizophrenic patients who require prolonged parenteral antipsychotic therapy (depot intramuscular decanoate)
  • Bipolar disorder
  • Behavioral disturbances in dementias
  • Neuroleptic-induced deficit syndrome
  • Akathisia
  • Extrapyramidal symptoms, Parkinsonism, tardive dyskinesia, tardive dystonia
  • Galactorrhea, amenorrhea
  • Dizziness, sedation
  • Dry mouth, constipation, urinary retention, blurred vision
  • Decreased sweating
  • Hypotension, tachycardia, hypertension
  • Weight gain